|
Question | Discussion | References | CME Credit
Case 3: References
- Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism
of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality.
2004;16:36-44.
[ PubMed
Abstract]
- Gourevitch MN, Friedland GH. Interactions
between methadone and medications used to treat HIV infection: A review.
Mt Sinai J Med. 2000; 67:429-36.
[ PubMed
Abstract]
- Clarke SM, Mulcahy FM, Tjia J, Reynolds
HE, Gibbons SE, Barry MG, Back DJ. Pharmacokinetic interactions of
nevirapine and methadone and guidelines for use of nevirapine to treat
injection drug users. Clin Infect Dis. 2001;33:1595-7.
[ PubMed
Abstract]
- Clarke SM, Mulcahy FM, Tjia J, Reynolds
HE, Gibbons SE, Barry MG, Back DJ. The pharmacokinetics of methadone
in HIV-positive patients receiving the non-nucleoside reverse transcriptase
inhibitor efavirenz. Br J Clin Pharmacol. 2001; 51:213-7.
[ PubMed
Abstract]
- McCance-Katz EF, Farber S, Selwyn
PA, O'Connor A. Decrease in methadone levels with nelfinavir mesylate.
Am J Psychiatry. 2000;157:481.
[ PubMed
Abstract]
- Clarke S, Mulcahy F, Bergin C, Reynolds
H, Boyle N, Barry M, Back DJ. Absence of opioid withdrawal symptoms
in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
Clin Infect Dis. 2002;34:1143-5.
[ PubMed
Abstract]
- McCance-Katz EF, Rainey PM, Friedland
G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce
opiate withdrawal in methadone-maintained patients. Clin Infect Dis.
2003;37:476-82.
[ PubMed
Abstract]
- Hendrix CW, Wakeford J, Wire MB, et al. Pharmacokinetics
and pharmacodynamics of methadone enantiomers after coadministration
with amprenavir in opioid-dependent subjects. Pharmacotherapy. 2004;24:1110-21.
[ PubMed
Abstract]
- Cantilena S, Mcrea J, Blazes D, Winchell
G, Carides A, Royce C, et al. Lack of pharmacokinetic interaction between
indinavir and methadone (Abstract PI-74). Clin Pharmacol Ther. 1999;65:135.
[Back to Case 3 Question | Back
to Discussion]
CME Credit | Back to Top
|